3D cell clusters combined with a bioreactor system to enhance the drug metabolism activities of C3A hepatoma cell lines

NCUIR > college of Health Sciences and Technology > Department of Biomedical Sciences and Engineering > journal & Dissertation > Item 987654321/102661

Please use this identifier to cite or link to this item: https://ir.lib.ncu.edu.tw/handle/987654321/102661

Title:	3D cell clusters combined with a bioreactor system to enhance the drug metabolism activities of C3A hepatoma cell lines
Authors:	陳靖昀;Chen, Ching-Yun;Chiang, Tsai-Shin;Chiou, Ling-Ling;Lee, Hsuan-Shu;Lin, Feng-Huei
Contributors:	生醫理工學院生醫科學與工程學系
Date:	2016-01-01
Issue Date:	2026-04-23 11:14:30 (UTC+8)
Publisher:	Royal Society of Chemistry
Abstract:	摘要： Since clinical drugs need to be approved for their liver metabolism efficiency before commercialization, a powerful in vitro drug-screening platform is imperative and indispensable for the clinical medicine and pharmaceutical industries. An essential issue in the development of drug screening platforms is choosing cell candidates that mimic and perform cell/tissue functions of normal hepatic tissues in vivo . In this study, we developed a self-designed bioreactor system to provide and mimic an appropriate environment for systematic cell expansion, micro-tissue formation, and increased cellular cytochrome P450 (CYP) enzymatic activities. Since CYP3A4 is the most plentiful and crucial enzyme in drug metabolism among liver CYP superfamily members, we demonstrated that micro-tissue formation under three-dimensional dynamic conditions could enhance cellular CYP3A4 enzymatic activity, maintain cell viability, and preserve adhesive abilities. Furthermore, Ca-alginate scaffolds used in this study can be completely removed by a non-toxic chelating reagent (EDTA solution), and the functional micro-tissues can be collected by slow-speed centrifugation. In conclusion, these micro-tissues are advantageous and show great potential in in vitro drug metabolizing assays. Since clinical drugs need to be approved for their liver metabolism efficiency before commercialization, a powerful in vitro drug-screening platform is imperative and indispensable for the clinical medicine and pharmaceutical industries. 出版日期： 2016-11-02 資源來源： Royal Society of Chemistry 識別號： ISSN: 2050-750X 識別號： EISSN: 2050-7518 識別號： DOI: 10.1039/c6tb01627h
Appears in Collections:	[Department of Biomedical Sciences and Engineering ] journal & Dissertation

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	13	View/Open

社群 sharing

Loading...